# US 2021/0228509 A1 · Prodrug for the treatment of disease and injury of oxidative stress

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228509 A1
- Document ID: US20210228509A1
- Status: Published application
- Kind: A1
- Application number: 17/156,560
- Filed: 2021-01-23
- Published: 2021-07-29
- Earliest claimed: 2020-01-24
- Applicants: Nacuity Pharmaceuticals, Inc.
- Inventors: G. Michael Wall
- Web page: https://patentgrep.com/patent/US20210228509A1

## CPC

- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 9/0007: {Effervescent (A61K9/0065 takes precedence)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0043: {Nose}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 9/4841: {Filling excipients; Inactive ingredients}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61P 27/02: Ophthalmic agents
- A61P 39/06: Free radical scavengers or antioxidants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention includes a method for using diNACA as a prodrug to deliver diNACA, NACA and NAC to a mammal for therapeutic purposes to prevent or treat diseases or disorders involving oxidative stress. The method includes any disease that involves the therapeutic use of NACA or NAC as a therapeutic agent. Also, compositions and methods for the prevention, reduction or treatment of corneal endothelial cell loss in a patient that comprise providing the patient with an amount of at least one, alone or in combination, of N-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) (diNACA) to prevent or reduce the corneal endothelial cell loss or to prevent or treat presbyopia. DiNACA can be used to prevent or treat cataracts.

## Claims

### Claim 1

A method for using diNACA as a prodrug to deliver diNACA, NACA or NAC to treat diseases or disorders of oxidative stress in a mammal comprising, consisting essentially of, or consisting of: administering a therapeutically effective amount of diNACA, NACA, NAC, or combinations thereof to the mammal to prevent or treat one or more diseases or disorders of oxidative stress selected from AIDS, antivenom, beta-thalassemia, cataract, cataracts in a subject that does not have diabetes, chronic obstructive pulmonary disease, corneal endothelial cell loss, diabetes and diabetes-induced ulcers, macular degeneration, contrast-induced nephropathy, asthma, lung contusion, macular degeneration, methamphetamine-induced oxidative stress, multiple sclerosis, Parkinson's disease, platelet apoptosis, presbyopia, Tardive dyskinesia, Alzheimer disease, HIV, HIV-1-associated dementia, mitochondrial diseases, myocardial myopathy, neurodegenerative diseases, pulmonary fibrosis, retinitis pigmentosa, Usher syndrome, Stargardt syndrome, age-related macular degeneration, skin pigmentation, skin in need of rejuvenation, mucous accumulation or thickening in the respiratory system, low spermatogenesis and male infertility, beta-thalassemia, antimicrobial infection, HIV associated dementia, methamphetamine abuse, cocaine abuse, alcohol abuse, skin hyperpigmentation or Friedreich's ataxia.

### Claim 2 (depends on 1)

The method of claim 1, wherein the prodrug to deliver diNACA, NACA and NAC, to a mammal is administered orally, intravenously, intramuscularly, enterally, intraocularly, subretinally, intravitreally, topically, transdermally, ocularly (eye drops, insert, injection or implant), sublingually, rectally or by injection or inhalation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the diNACA is administered orally, intravenously, intramuscularly, enterally, intraocularly, subretinally, intravitreally, topically, transdermally, ocularly (eye drops, insert, injection or implant), sublingually, rectally or by injection or inhalation.

### Claim 4 (depends on 1)

The method of claim 1, wherein diNACA is administered to a mammal for therapeutic prevention of at least one of: of mucous accumulation or thickening in the respiratory system, retinitis pigmentosa, low spermatogenesis and male infertility, Parkinson's disease, beta-thalassemia, HIV associated dementia, methamphetamine abuse, cocaine abuse, alcohol abuse, skin hyperpigmentation or skin in need of rejuvenation, presbyopia, macular degeneration, hepatotoxicity, concussion, exposure to ionizing radiation, traumatic brain injury or spinal cord injury.

### Claim 5 (depends on 1)

The method of claim 1, wherein diNACA is administered to a mammal for therapeutic treatment of at least one of: mucous accumulation or thickening in the respiratory system, retinitis pigmentosa, low spermatogenesis and male infertility, Parkinson's disease, beta-thalassemia, HIV associated dementia, methamphetamine abuse, cocaine abuse, alcohol abuse, skin hyperpigmentation or skin in need of rejuvenation, presbyopia, macular degeneration, hepatotoxicity, concussion, exposure to ionizing radiation, traumatic brain injury or spinal cord injury.

### Claim 6

A method for the prevention of corneal endothelial cell loss in a human subject comprising:
identifying a human patient in need of treatment for corneal endothelial cell loss; and
administering to the human patient a therapeutically effective amount of at least one of N-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) sufficient to prevent or reduce the corneal endothelial cell loss.

### Claim 7 (depends on 6)

The method of claim 6, wherein NACA or diNACA is provided in or with a pharmaceutically acceptable carrier which can be a formulation, insert or implant.

### Claim 8 (depends on 6)

The method of claim 6, wherein the corneal cell loss is due to cataract or ophthalmic surgery and the composition is provided to the subject after cataract or ophthalmic surgery, or cataracts when the human subject does not have diabetes.

### Claim 9 (depends on 6)

The method of claim 6, wherein the at least one of NACA or diNACA is administered orally, intravenously, intramuscularly, enterally, intraocularly, subretinally, intravitreally, topically, ocularly (eye drops, insert or implant), sublingually, or rectally or by injection, nasal spray or inhalation.

### Claim 10 (depends on 6)

The method of claim 6, wherein the at least one of NACA or diNACA is administered in daily doses of about 0.01 to 150 mg/Kg.

### Claim 11 (depends on 6)

The method of claim 6, wherein the at least one of NACA or diNACA is administered two or three times daily.

### Claim 12 (depends on 6)

The method of claim 6, wherein the at least one of NACA or diNACA is administered with a second active agent selected from at least one of ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, or phosphoric acid.

### Claim 13 (depends on 6)

The method of claim 6, wherein the dose for administration is about 0.001, 0.01, 0.1, 1, 10, 100, 150, 150, 300, 333, 400, 500, 600, 700, 750, 800, 900, 1,000, 2,500, 5,000, 7,500, or 10,000 mg per dose.

### Claim 14 (depends on 6)

The method of claim 6, wherein the at least one of NACA or diNACA is delivered orally via a mini-tablet, capsule, tablet, effervescent, dual release, mixed release, sachet, powder, ocular insert, ocular implant, eye drop or liquid.

### Claim 15 (depends on 6)

The method of claim 6, wherein the at least one of NACA or diNACA is administered prophylactically, post-surgically or after other procedures or treatments, to prevent or reduce corneal endothelial cell loss.

### Claim 16

A method for the prevention or reduction of presbyopia in a human subject comprising:
identifying a human in need of treatment for presbyopia; and
administering to the human a therapeutically effective amount of of NAC, N-acetylcysteine amide (NACA), or (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) sufficient to prevent or reduce presbyopia.

### Claim 17 (depends on 16)

The method of claim 16, wherein the at least one of NAC, NACA or diNACA is provided in or with a pharmaceutically acceptable carrier.

### Claim 18 (depends on 16)

The method of claim 16, wherein the at least one of NAC, NACA or diNACA is administered orally, intravenously, intramuscularly, intranasally, enterally, intraocularly, subretinally, intravitreally, topically, ocularly (eyedrops, insert, injection or implant), sublingually, rectally or by injection, nasal spray or inhalation.

### Claim 19 (depends on 16)

The method of claim 16, wherein at least one of NAC, NACA or diNACA is administered in daily doses of about 0.01 to 150 mg/Kg.

### Claim 20 (depends on 16)

The method of claim 16, wherein at least one of NAC, NACA or diNACA is administered two or three times daily.

### Claim 21 (depends on 16)

The method of claim 16, wherein at least one of NAC, NACA or diNACA is administered with a second active agent selected from at least one of ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, or phosphoric acid.

### Claim 22 (depends on 16, 323)

The method of claim 16, wherein the dose for administration is about 0.001, 0.01, 0.1, 1, 10, 100, 150, 150, 300, 333, 400, 500, 600, 700, 750, 800, 900, 1,000, 2,500, 5,000, 7,500, or 10,000 mg per dose. 39. The method of claim 323, wherein at least one of NAC, NACA or diNACA is delivered orally via a mini-tablet, capsule, tablet, effervescent, dual release, mixed release, sachet, powder, or liquid.

### Claim 23 (depends on 16)

The method of claim 16, wherein the therapeutically effective amount preferably refers to the amount of a therapeutic agent that decreases the loss or improves visual acuity.

### Claim 24

A method for the prevention or reduction of cataract by providing a subject in need thereof a therapeutically effective amount of diNACA and administering to the human patient a therapeutically effective amount of diNACA to prevent or treat cataract.

### Claim 25 (depends on 24)

The method of claim 24, wherein the diNACA is administered before, during of post-vitrectomy surgery.

### Claim 26 (depends on 24)

The method of claim 24, wherein the diNACA is administered orally, intravenously, intramuscularly, intranasally, enterally, intraocularly, subretinally, intravitreally, topically, sublingually, or rectally, ocularly via eyedrops, insert or implant, or by injection, nasal spray, or inhalation.
